Amicus Therapeutics, Inc. (FOLD) News
Filter FOLD News Items
FOLD News Results
|Loading, please wait...|
FOLD News Highlights
- FOLD's 30 day story count now stands at 15.
- Over the past 16 days, the trend for FOLD's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about FOLD are EBIX, ARRY and CIFR.
Latest FOLD News From Around the Web
Below are the latest news stories about Amicus Therapeutics Inc that investors may wish to consider to help them evaluate FOLD as an investment opportunity.
Gainers: Clearside Biomedical (CLSD) +13%, Ebix (EBIX) +7%, Cipher Mining (CIFR) +6%, Array Technologies (ARRY) +5%, Amicus Therapeutics (FOLD) +4%. Losers: Perella Weinberg
Amicus Therapeutics (FOLD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
No summary available.
In a report released today, Gil Blum from Needham maintained a Hold rating on Amicus (FOLD – Research Report). The company's shares closed last Monday at $9.45, close to its 52-week low of $8.60. According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -34.8% and a 4.2% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Currently, the analyst consensus on Amicus is a Moderate Buy with an average price target of $16.25, which is a 47.9% upside from current levels.
Leerink Partners analyst Joseph Schwartz reiterated a Hold rating on Amicus (FOLD – Research Report) yesterday. The company's shares closed last Tuesday at $9.26, close to its 52-week low of $8.60. According to TipRanks.com, Schwartz is a 3-star analyst with an average return of 2.5% and a 41.3% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals. Amicus has an analyst consensus of Moderate Buy, with a price target consensus of $16.25, implying a 74.9% upside from current levels. In a report issued on January 5, Berenberg Bank also maintained a Hold rating on the stock with a $14.
Amicus Therapeutics <
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
Full-Year 2021 Galafold® Revenue of ~$306M, Representing 17% YoY Growth Expect Double-Digit Growth (15-20%) of 2022 Galafold Revenue with $350M-$365M in Global Sales U.S. and EU Regulatory Reviews Underway for AT-GAA in Pompe Disease AT-GAA Global Launch Preparations Accelerating Cash Flow and Balance Sheet Sufficient to Achieve Self-Sustainability and Profitability by 2023 PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnolog
PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022 at 3:45 p.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) i
Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...